Animal studies demonstrate that hematopoietic stem cells, and not differentiated progenitors, are responsible for early hematopoietic reconstitution following autologous transplantation. 
Principles of Hematopoietic Stem-cell Mobilization
Although unstimulated marrow or blood may serve as a source of stem cells for autologous transplantation, the use of 'mobilized' peripheral blood is a better source of cells and is now uniformly utilized for this purpose. The number of CD34 + cells in the blood is dramatically increased by mobilizing them from the marrow with hematopoietic growth factors. 5, 6 Growth factors, particularly granulocyte-colony-stimulating factor (G-CSF), alone or in combination with certain non-stem-cell-toxic chemotherapeutic agents (most commonly cyclophosphamide or etoposide), are the most frequently used mobilizing agents. The number of CD34 + cells in the bloodstream is increased several-fold by these measures, and CD34 + cells are efficiently collected by apheresis of approximately four total patient blood volumes or of about 20 liters. The number of CD34 + cells/kg in the collection is easily tabulated and the need for additional apheresis is determined. In order to ensure reliably rapid hematopoietic recovery, most centers target a dose of 4-5x10 6 CD34 + cells/kg, but doses ≥2x10 6 
Mobilization Methods
The 71.6%. 12 The enhanced mobilization resulted in rapid and durable hematologic recovery after transplantation. Alternatively, high-dose cyclophosphamide [16] [17] [18] Additional treatment, e.g. with AMD3100, might then be initiated only in those patients at risk for inadequate CD34 + cell harvests in order to 27 Our patients who required more apheresis days, particularly those requiring five or more procedures, had significantly slower neutrophil recovery, slower platelet recovery, and a higher risk for failure to achieve platelet recovery within eight weeks post-transplantation. 28 These data serve as a reminder that CD34 + cell number is only a surrogate for the cells that repopulate the marrow. Additional clinical circumstances may be identified in which its usefulness as a single predictor of hematopoietic recovery is limited. Interestingly, the need for numerous aphereses also identified patients at high risk for the development of therapy-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), as had been previously reported. 29 As the number of autologous transplants performed annually continues to increase, 30 it is fitting that the mechanisms of stem-cell mobilization 
